Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 501–600 of 1,002
A machine learning model that emulates experts’ decision making in vancomycin initial dose planning
Matsuzaki, T., Kato, Y., Mizoguchi, H., & Yamada, K. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.02.005 · Cited by 30
Keel, R. A., Sutherland, C. A., Aslanzadeh, J., Nicolau, D. P., & Kuti, J. L. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.08.006 · Cited by 29
The association of elevated trough serum vancomycin concentrations with obesity
Richardson, J., Scheetz, M. H., & O’Donnell, E. P. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.03.007 · Cited by 29
“Trough SVC measurement no more than 2 h prior to the fourth or subsequent dose was done as recommended by current guidelines for therapeutic drug monitoring of vancomycin.[9].”
Clemens, E. C., Chan, J. D., Lynch, J. B., & Dellit, T. H. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.08.002 · Cited by 29
Patel, N., VanDeWall, H., Tristani, L., Rivera, A., Woo, B., Dihmess, A., Li, H. K., Smith, R. P., & Lodise, T. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr522 · Cited by 30
Riedel, S. F., Neoh, K. M., Eisinger, S. W., Dam, L. M., Tekle, T., & Carroll, K. C. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00957-14 · Cited by 29
“of alternate antimicrobial agents is recommended for certain clinical settings when vancomycin MICs are 1 g/ml (6, 16).”
BackgroundInvasive community-associated MRSA infections: epidemiology and antimicrobial management
Pichereau, S., & Rose, W. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511614 · Cited by 31
“In both Europe and US, the recommended standard of care is high-dose vancomycin therapy to achieve a trough of 15 -- 20 mg/l for severe MRSA infections [26,35].”
BackgroundShah, P. J., Bergman, S., Graham, D. R., & Glenn, S. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014544786 · Cited by 31
Herten, M., Idelevich, E. A., Sielker, S., Becker, K., Scherzinger, A. S., Osada, N., Torsello, G. B., & Bisdas, T. (2017) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.902879 · Cited by 29
“Therapeutic drug monitoring is recommended for patients receiving vancomycin to ensure its safe and effective use [32].”
BackgroundNakakura, I., Sakakura, K., Imanishi, K., Sako, R., & Yamazaki, K. (2019) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-019-0138-2 · Cited by 29
Miranda, T. M. M., Belucci, T. R., Malagutti, S. R., & Furtado, G. H. C. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1602-8 · Cited by 28
Liu, Y., Mack, J. O., Shojaee, M., Shaver, A., George, A., Clarke, W. A., Patel, N., & Arroyo‐Currás, N. (2023) · ACS Sensors · doi:10.1021/acssensors.3c01868 · Cited by 28
The clinical efficacy and safety of vancomycin loading dose
Mei, H., Wang, J., Che, H., Wang, R., & Cai, Y. (2019) · Medicine · doi:10.1097/md.0000000000017639 · Cited by 28
Kovačević, T., Miljković, B., Kovačević, P., Dragić, S., Momčićević, D., Avram, S., Jovanović, M., & Vučićević, K. M. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.10.012 · Cited by 28
Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices
Carland, J. E., STOCKER, S. L., Baysari, M. T., Li, C. N., Själin, J., Moran, M., Tang, S. S. L., Sandaradura, I., Elhage, T., Gilbey, T. L., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14834 · Cited by 28
“Consequently, the 2009 international guidelines recommended monitoring trough concentrations as a surrogate measure of drug exposure.(3) However, the revised international guidelines(4) recommend AUC-guided dosing.”
Hall, R. G., Giuliano, C. A., Haase, K. K., Hazlewood, K. A., Frei, C. R., Forcade, N. A., Brouse, S. D., Bell, T., Bedimo, R., & Álvarez, C. A. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-104 · Cited by 28
“dose IV administered every eight to 12 hours) [7].”
BackgroundMethodInfluentialA Randomized Controlled Trial of a Vancomycin Loading Dose in Children
Demirjian, A., Finkelstein, Y., Nava‐Ocampo, A. A., Arnold, A. D., Jones, S. M., Monuteaux, M. C., Sandora, T. J., Patterson, A., & Harper, M. B. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182a26774 · Cited by 28
Vancomycin and nephrotoxicity: Just another myth?
Davies, S. W., Guidry, C. A., Petroze, R. T., Hranjec, T., & Sawyer, R. G. (2013) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3182a74b70 · Cited by 32
“According to the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, the current recommended guidelines for vancomycin dosing are 15 mg/kg to 20 mg/kg (actual body weight) given every 8 hours to 12 hours for most patients with n…”
BackgroundAubron, C., Corallo, C., Nunn, M. O., Dooley, M. J., & Cheng, A. C. (2011) · Annals of Pharmacotherapy · doi:10.1177/106002801104501001 · Cited by 31
Tremblay, S., Lau, T. T. Y., & Ensom, M. H. H. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r726 · Cited by 31
Staphylococcus aureus – antimicrobial resistance and the immunocompromised child
McNeil, J. C. (2014) · Infection and Drug Resistance · doi:10.2147/idr.s39639 · Cited by 30
“From studies in adults, primarily with S. aureus bacteremia, there is evidence to suggest improved clinical outcomes with vancomycin troughs of 15–20 µ g/mL. 95 Many experts recommend similar goal levels in pediatric patients, yet the evidence to support this is limited.”
Petejová, N., Martínek, A., Zahalkova, J., Ďuricová, J., Brozmanová, H., Urbánek, K., Grundmann, M., Plášek, J., & Kacířová, I. (2012) · Biomedical Papers · doi:10.5507/bp.2012.092 · Cited by 28
Golenia, B. S., Levine, A. R., Moawad, I., Yeh, D. D., & Arpino, P. A. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2013.01.004 · Cited by 28
“This ratio is supported as the pharmacodynamic index necessary for maximum bactericidal eradication of organisms with an MIC 1 mg/mL or less [5].”
InfluentialOptimizing Antibiotic Pharmacodynamics for Clinical Practice
Connors, K. P. (2013) · Pharmaceutica Analytica Acta · doi:10.4172/2153-2435.1000214 · Cited by 33
“This concept, unfortunately, is directly opposed to guidelines that indicate that a trough of 15-20 mcg/ml is sufficient for therapeutic drug monitoring of the drug [72].”
BackgroundDib, J. G., Al‐Tawfiq, J. A., Abdulmohsin, S. A., Mohammed, K., & Jenden, P. D. (2009) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2009.07.002 · Cited by 28
Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application
Barber, K. E., Bell, A. M., Stover, K. R., & Wagner, J. L. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0420-z · Cited by 30
“In patients who are frail or thin, loading doses should still be initiated at 25–30 mg/kg based on actual body weight, especially if the actual body weight is less than the ideal body weight, in patients with severe infections from suspected MRSA [9].”
BackgroundMethodInfluentialSmith, J. R., Frens, J. J., Snider, C. B., & Claeys, K. C. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.001 · Cited by 29
Extremely high levels of vancomycin can cause severe renal toxicity
Barceló‐Vidal, J., Rodríguez, E., & Grau, S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s171669 · Cited by 28
“Currently, these toxicities are related to long periods of treatment, concomitant nephrotoxic agents, high dosages, and high vancomycin plasma trough levels.(1) Vancomycin has usually been associated with nephrotoxicity; nevertheless, the direct damage caused by this glycopeptide is still unknown.”
Chu, Y., Luo, Y., Quan, X., Jiang, M., & Zhou, B. (2019) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2019.09.001 · Cited by 28
Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile
Henson, K. E. R., Levine, M. T., Wong, E. A. H., & Levine, D. P. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1068118 · Cited by 33
Self-citationWeight-Based Loading of Vancomycin in Patients on Hemodialysis
Brown, M., Polisetty, R. S., Gracely, E. J., Çuhaci, B., & Schlecht, H. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir322 · Cited by 28
“In summary, we found that the weight-based loading dose of vancomycin for patients with ESRD who receive HD is very similar to that in current guideline recommendations for those patients with normal renal function.”
BackgroundInfluentialJavorská, L., Krčmová, L. K., Solich, P., & Kaška, M. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.04.029 · Cited by 27
Pan, K., Wu, Y., Chen, C., Chen, Z., Xu, J., Cao, L., Xu, Q., Wu, W., Dai, P., Li, X., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13594 · Cited by 27
Fan, T., Hu, X., Tang, S., Liu, X., Wang, Y., Deng, H., You, X., Jiang, J., Li, Y., & Song, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00094 · Cited by 27
Komoto, A., Maiguma, T., Teshima, D., Sugiyama, T., & Haruki, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203453 · Cited by 29
Abraham, J., Sinnollareddy, M., Roberts, M. S., Williams, P. A. H., Peake, S., Lipman, J., & Roberts, J. A. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.021 · Cited by 27
Kebriaei, R., Rice, S., Stamper, K. C., & Rybak, M. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01743-18 · Cited by 27
Self-citationAlhameed, A. F., Khansa, S. A., Hasan, H., Ismail, S., & Aseeri, M. A. (2019) · Pharmacy · doi:10.3390/pharmacy7010020 · Cited by 27
“It has been reported by previous studies that practicing therapeutic drug monitoring according to consensus recommendations of guidelines will more likely lead to target trough levels, which correlate with clinical efficacy [14].”
BackgroundMethodVancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock
Masich, A. M., Kalaria, S. N., Gonzales, J. P., Heil, E. L., Tata, A. L., Claeys, K. C., Patel, D. M., & Gopalakrishnan, M. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2367 · Cited by 35
“7) SOFA score 11 (6, 17) qSOFA score 2 (2) Infection source Bacteremia 8 (50) Pneumonia 4 (25) Gastrointestinal 3 (19) Skin and soft tissue 1 (6) Bacteria isolated MRSA: 2 (13) CoNS: 4 (25) Streptococcus viridans: 1 (6) Staphylococcus hominis: 1 (6) Enterobacter cloacae: 1 (6) Candida albicans: 1 (6) Acinetobacter bau…”
Glycopeptide Hypersensitivity and Adverse Reactions
Huang, V., Clayton, N. A., & Welker, K. (2020) · Pharmacy · doi:10.3390/pharmacy8020070 · Cited by 29
Oda, K., Jono, H., Kamohara, H., Nishi, K., Tanoue, N., & Saito, H. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02820-0 · Cited by 29
Group B Streptococcus in Pregnancy
Mei, J. Y., & Silverman, N. S. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2023.02.009 · Cited by 28
Shokouhi, S., & Darazam, I. A. (2014) · Journal of Infection · doi:10.1016/j.jinf.2014.06.010 · Cited by 27
Liang, R., Yong, X., Duan, Y.-Q., Tan, Y., Zeng, P., Zhou, Z., Jiang, Y., Wang, S., Jiang, Y.-P., Huang, X., et al. (2014) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-014-1712-2 · Cited by 32
Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients
Kim, A. J., Lee, J., Choi, S. A., & Shin, W. G. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.06.022 · Cited by 27
Liu, X., Li, J., Feng, Z., Luo, Y., Veening, J., & Zhang, J.-R. (2017) · Journal of Bacteriology · doi:10.1128/jb.00054-17 · Cited by 30
Awdishu, L. (2017) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000453 · Cited by 27
Mader, M. M.-D., Czorlich, P., König, C., Fuhrmann, V., Kluge, S., Westphal, M., & Grensemann, J. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3680-z · Cited by 30
Gregory, E. R., Burgess, D. R., Cotner, S. E., VanHoose, J. D., Flannery, A. H., Gardner, B. M., Autry, E. B., Forster, D. W., Burgess, D. S., & Wallace, K. L. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019834369 · Cited by 29
“However, vancomycin has been monitored historically using a trough concentration as a surrogate for AUC.(3) The widely recommended trough goal of 15 to 20 mg/L for severe methicillin-resistant Staphylococcus aureus (MRSA) infections was thought to correlate with an AUC of 400 mg h/L, but evidence has suggested otherwi…”
BackgroundMethodInfluentialCollins, C. D., & Schwemm, A. K. (2015) · Value in Health · doi:10.1016/j.jval.2015.04.007 · Cited by 30
“As a result, no clear preference between agents is specified and international guidelines fail to delineate a primary treatment recommendation [5,11].”
BackgroundEmpiric Vancomycin Use in Febrile Neutropenic Oncology Patients
Libuit, J., Whitman, A. M., Wolfe, R., & Washington, C. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu006 · Cited by 26
“propriateness of the initial vancomycin-dosing regimen based on a dose of 15–20 mg/kg (actual body weight) given every 8–12 hours for patients with normal renal function [6].”
BackgroundShahrami, B., Najmeddin, F., Mousavi, S., Ahmadi, A., Rouini, M. R., Sadeghi, K., & Mojtahedzadeh, M. (2016) · Critical Care Research and Practice · doi:10.1155/2016/1245815 · Cited by 26
“Unlike the methods used in individualization of vancomycin noted in clinical guidelines that recommend measuring trough serum concentration at steady state conditions [13, 14], we found that early individualization and first-dose monitoring of vancomycin let the patients achieve therapeutic serum concentrations earlie…”
BackgroundMethodInfluentialEl catéter periférico: el gran olvidado de la infección nosocomial
Capdevila, J. A. (2013) · Revista española de quimioterapia. Suplemento · Cited by 57
Katip, W., Okonogi, S., & Oberdorfer, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.773994 · Cited by 26
Sheridan, K. R., Potoski, B. A., Shields, R. K., & Nau, G. J. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1247 · Cited by 26
“Although increasing the dose of vancomycin will similarly lead to increased concentrations in the vitreous humor, vancomycin pharmacodynamic activity is not solely concentration dependent.(13) Further, a recent report suggested that higher daily doses of vancomycin are associated with an increased risk of nephrotoxici…”
BackgroundBiopsy-Proven Acute Tubular Necrosis due to Vancomycin Toxicity
Shah-Khan, F. M., Scheetz, M. H., & Ghossein, C. (2011) · International Journal of Nephrology · doi:10.4061/2011/436856 · Cited by 26
“Goal troughs and monitoring schemes were performed according to national VAN guidelines [4].”
Docobo-Pérez, F., López-Rojas, R., Domínguez-Herrera, J., Me, J.-M., Pichardo, C., Ibáñez-Martínez, J., & Pachón, J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks142 · Cited by 26
Westphal, N., Plicht, B., & Naber, C. K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0481 · Cited by 38
Methicillin-Resistant Staphylococcus aureus USA300 Clone as a Cause of Lemierre's Syndrome
Chanin, J. M., Marcos, L. A., Thompson, B., Yusen, R. D., Dunne, W. M., Warren, D. K., & Santos, C. A. Q. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02507-10 · Cited by 26
“Vancomycin serum trough levels should remain between 15 and 20 g/ml for the duration of therapy (30).”
BackgroundStrategies for appropriate antibiotic use in intensive care unit
da Silva, C. D. R., & Silva, M. (2015) · Einstein (São Paulo) · doi:10.1590/s1679-45082015rw3145 · Cited by 75
Bonazza, S., Bresee, L. C., Kraft, T., Ross, B. C., & Dersch‐Mills, D. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.6.486 · Cited by 26
Evaluation of Continuous Infusion Vancomycin Administration in a Critically Ill Trauma Population
Bissell, B. D., Riggi, G., & Morrison, C. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618768749 · Cited by 26
“572 Journal of Intensive Care Medicine 35(6)”
BackgroundZonozi, R., Wu, A., Shin, J., Secora, A. M., Coresh, J., Inker, L. A., Chang, A. R., & Grams, M. E. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.034 · Cited by 26
Significant publications on infectious diseases pharmacotherapy in 2015
Babic, J. T., Sofjan, A. K., Babin, M., Echevarria, K. L., Ikwuagwu, J. O., Lam, W.-Y. M., Aitken, S. L., & Perez, K. K. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160090 · Cited by 26
“The AHA-recommended vancomycin trough concentration was changed from 10–15 to 10–20 mg/L, based on PK–PD data supporting attainment of a target ratio of 24-hour area under the curve to minimum inhibitory concentration (MIC) of ≥400 if the vancomycin MIC is 1 mg/L or less.(41) Gentamicin is no longer recommended by AHA…”
MethodChallenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates
Pham, J. T. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.6.476 · Cited by 26
Use of Antibacterial Agents in Renal Failure
Gilbert, B. C., Robbins, P., & Livornese, L. L. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.009 · Cited by 26
Dose modulation: A new concept of antibiotic therapy in the critically ill patient?
Gonçalves-Pereira, J., & Paiva, J.-A. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.11.018 · Cited by 27
“High vancomycin trough serum concentration may also be associated with nephrotoxicity and aggressive dosing is nowadays recommended [36] for difficult-to-treat infections, although there are scarce data to support this approach.”
BackgroundThe potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults
Moenster, R. P., Linneman, T. W., Call, W. B., Kay, C. L., McEvoy, T. A., & Sanders, J. L. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12030 · Cited by 25
“Its long history of use, available clinical data and relatively easy-touse pharmacokinetic dosing nomograms and models are some of vancomycin’s advantages.(1,3,6,7) Garazzino et al.”
BackgroundHolmes, N. E., Turnidge, J. D., Munckhof, W., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S., Warren, S. J. C., Gao, W., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12168 · Cited by 28
“Vancomycin susceptibility is undoubtedly important in treatment outcome when strains are intermediate or resistant (broth microdilution MIC >2 mg/L), and it is difficult to achieve target pharmacokinetic–pharmacodynamic measures in vancomycin-treated patients using recommended dosing regimens when the vancomycin MIC i…”
BackgroundSuchartlikitwong, P., Anugulruengkitt, S., Wacharachaisurapol, N., Jantarabenjakul, W., Sophonphan, J., Theerawit, T., Chatsuwan, T., Wattanavijitkul, T., & Puthanakit, T. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1498 · Cited by 25
A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia
He, N., Dong, F., Liu, W., & Zhai, S. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s239095 · Cited by 26
Shimamoto, Y., Verstegen, R. H. J., Mizuno, T., Schechter, T., Allen, U., & Ito, S. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab302 · Cited by 25
Sultan, A. R., Tavakol, M., Toom, N. A. L.-D., Croughs, P. D., Verkaik, N. J., Verbon, A., & van Wamel, W. J. B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0260272 · Cited by 29
Vancomycin Dosing Considerations in a Real‐World Cohort of Obese and Extremely Obese Patients
Morrill, H. J., Caffrey, A. R., Noh, E., & LaPlante, K. L. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1625 · Cited by 25
“, after at least three vancomycin doses) and measured ≤ 2 hours before the next vancomycin dose (Figure 1).(8) Patients were included if they had no evidence of acute kidney injury (defined as an increase in serum creatinine concentration of 0.”
BackgroundInfluentialBarie, P. S., & Wilson, S. E. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.02.039 · Cited by 25
The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis
Stevenson, S. J., Tang, W., Cho, Y., Mudge, D. W., Hawley, C. M., Badve, S. V., & Johnson, D. W. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2013.00156 · Cited by 25
“aureus exposure to trough serum vancomycin concentrations of < 10 mg/L can induce vancomycin resistance (15).”
BackgroundPichereau, S., Pantrangi, M., Couet, W. R., Badiou, C., Lina, G., Shukla, S. K., & Rose, W. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05113-11 · Cited by 26
“(54), and vancomycin at 1,000 mg every 12 h (49).”
Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients
Hong, L. T., Goolsby, T. A., Sherman, D. S., Mueller, S. W., Reynolds, P., Cava, L. F., Neumann, R. T., & Kiser, T. H. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.06.012 · Cited by 25
“Target trough levels for INT dosing were 15 to 20 mg/L [3,4].”
BackgroundMethodResultInfluentialOptimizing initial vancomycin dosing in burn patients
Elligsen, M., Walker, S. A. N., Walker, S. E., & Simor, A. E. (2010) · Burns · doi:10.1016/j.burns.2010.06.005 · Cited by 30
Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care.
Petrosillo, N., Drapeau, C. M. J., Agrafiotis, M., & Falagas, M. E. (2010) · PubMed · Cited by 25
Sheng, Y., & Zhou, B. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.02.061 · Cited by 25
Kim, T., Chong, Y. P., Park, K., Bang, K. M., Park, S., Kim, S., Jeong, J., Lee, S., Choi, S., Woo, J. H., et al. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.351 · Cited by 25
“Vancomycin dose was adjusted according to the report published by the American Society of Health-System Pharmacists [22].”
MethodLi, Y., & Xu, W. (2017) · Bioscience Reports · doi:10.1042/bsr20171125 · Cited by 25
Berthaud, R., Benaboud, S., Hirt, D., Genuini, M., Oualha, M., Castelle, M., Briand, C., Artru, S., Norsa, L., Boyer, O., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-19 · Cited by 25
“Our definition of vancomycinrelated nephrotoxicity had already been used in many studies (20, 22, 28, 29).”
MethodNathwani, D. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70546-1 · Cited by 25
Infectious Arthritis of Native Joints
Ohl, C. A., & Forster, D. W. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00105-3 · Cited by 29
Mendes, R. E., Sader, H. S., Flamm, R. K., Farrell, D. J., & Jones, R. N. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04616-14 · Cited by 26
“Recent consensus guidelines recommend 58 alternative therapeutic agents for the management of infections due to MRSA strains with reduced 59 susceptibility to vancomycin (11, 12).”
BackgroundMoenster, R. P., Linneman, T. W., Finnegan, P. M., & McDonald, J. R. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.06.013 · Cited by 24
Valour, F., Blanc-Pattin, V., Freydière, A.-M., Bouaziz, A., Chanard, E., Lustıg, S., Ferry, T., & Laurent, F. J. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.026 · Cited by 24
“Vancomycin infusion requires close monitoring, and plasma trough level should be obtained to ensure steady state has been achieved; ordose adjustment is required (Rybak et al., 2009).”
BackgroundBlumenthal, K. G., Youngster, I., Shenoy, E. S., Banerji, A., & Nelson, S. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02504-13 · Cited by 24
“In addition to efficacy concerns, the use of vancomycin is associated with higher toxicity than the use of -lactam antibiotics, (45, 49, 57, 58), and its overuse can lead to greater antimicrobial resistance (59, 60).”
BackgroundNekidy, W. S. E., El‐Masri, M. M., Umstead, G. S., & Dehoorne-Smith, M. L. (2012) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v65i6.1191 · Cited by 24
“of vancomycin, with a target trough serum concentration of 5–10 mg/L.(3,7,15,16) This practice has resulted in the emergence of less susceptible strains of MRSA.”
BackgroundMethodInfluentialFujii, S., Takahashi, S., Makino, S., Kunimoto, Y., Nakata, H., Noda, N., Sakurai, K., & Miyamoto, A. (2013) · Chemotherapy · doi:10.1159/000356756 · Cited by 24
Vancomycin dosing and monitoring 2 years after the guidelines
Lomaestro, B. M. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.46 · Cited by 25
Self-citationPediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring
Balch, A. H., Constance, J. E., Thorell, E. A., Stockmann, C. R., Korgenski, E. K., Campbell, S., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.402 · Cited by 24
“Concstatus1⁄4 “Low” indicates that a concentration was below guideline recommendations and was updated in 2011 to reflect publication of the pediatric guidelines.(8) The low trough flag reflects these changing recommendations and classifies any patient in the ICU as seriously ill.”
BackgroundMethodInfluentialVancomycin dosing in children: what is the question?
Cole, T. S., & Riordan, A. I. (2013) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-304169 · Cited by 24
Dosing of antibacterial agents in obese adults: does one size fit all?
Payne, K. D., & Hall, R. G. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.912942 · Cited by 24
“Based upon the preponderance of the current data, current consensus guidelines recommend dosing vancomycin based on TBW, with a maximum of 2 g per dose prior to adjustment with therapeutic drug monitoring [36,37].”
BackgroundPharmacokinetics and Pharmacodynamics of Anti-infective Agents
Pai, M. P., Cottrell, M. L., Kashuba, A. D. M., & Bertino, J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00019-9 · Cited by 26
Pai, M. P. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.094 · Cited by 26
“TDM permits adjustment of the dosage of vancomycin within 48 hours of initiation in most obese patients.(23) Innovative Bayesian and practical approaches to compute the “right” dose have been developed and should be applied.”
BackgroundLodise, T. P., Redell, M. A., Armstrong, S. O., Sulham, K. A., & Corey, G. R. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw274 · Cited by 24
Hadi, M., & Mollaei, T. (2018) · Electroanalysis · doi:10.1002/elan.201800497 · Cited by 24
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.